Table 1.
Baseline comparisons between Exercise and Standard Clinical Care participants.
| KERRYPNX | Standard Clinical Care (n = 8) | Exercise (n = 12) |
|---|---|---|
| Demographics | ||
| Age, yrs | 44.9 (36.8, 55.0) | 53.9 (45.7, 63.6) |
| Female sex, n (%) | 3 (38) | 8 (67) |
| BMI, kg/m2 | 34.2 (29.9, 39.1) | 32.8 (29.7, 36.2) |
| Body weight, kg | 106.4 (89.1, 127.2) | 95.5 (87.4, 104.3) |
| Metabolic risk | ||
| Comorbidities, n (%) | ||
| Diabetes | 3 (38) | 5 (42) |
| Hyperlipidemia | 5 (63) | 7 (58) |
| Hypertension | 5 (63) | 12 (100) |
| Hemoglobin A1c, % | 6.1 (5.3, 7.0) | 6.4 (5.6, 7.4) |
| Glucose (fasting), mg/dL | 128.4 (97.1, 169.7) | 136.3 (115.2, 161.3) |
| HOMA-IR | 7.7 (4.0, 15.0) | 13.3 (9.2, 19.2) |
| VO2peak, mL/kg/min | 24.0 (19.8, 29.1) | 19.3 (15.8, 23.6) |
| Body fat, % | 39.1 (30.8, 49.7) | 42.3 (37.7, 47.5) |
| NASH phenotyping | ||
| Medications, n (%) | ||
| Vitamin E | 2 (25) | 3 (25) |
| GLP-1 agonist | 0 (0) | 1 (8) |
| Non-invasive tests | ||
| FIB-4 | 1.07 (0.47, 2.40) | 1.15 (0.85, 1.57) |
| NFS, Median (IQR) | −1.75 (2.74) | −1.51 (1.25) |
| Serum biomarkers | ||
| Adiponectin, ng/mL | 3272 (2211, 4843) | 3449 (2947, 4036) |
| CK-18, IU/L | 85.7 (31.1, 236.4) | 231.5 (76.3, 702.1) |
| FGF-21, ng/dL | 372.4 (246.8, 561.8) | 520.7 (346.1, 783.3) |
| PAI-1, ng/mL | 206.0 (120.1, 353.5) | 165.8 (124.0, 221.7) |
| Imaging biomarkers | ||
| Liver fat (MRI-PDFF), % | 19.0 (11.8, 30.6) | 20.5 (17.4, 24.2) |
| NAS | 5.0 (4.5, 5.4) | 5.1 (4.5, 5.7) |
| Steatosis | 2.3 (2.0, 2.7) | 2.5 (2.0, 3.0) |
| Lobular inflammation, Median (IQR) | 1.0 (1.0) | 1.3 (0.7) |
| Hepatocyte ballooning | 1.2 (0.9, 1.5) | 1.2 (1.0, 1.5) |
| Fibrosis stage, n (%) | ||
| 0/1 | 4 (50) | 7 (58) |
| 2 | 3 (38) | 2 (17) |
| 3 | 0 (0) | 3 (25) |
| 4 | 1 (12) | 0 (0) |
BMI = body mass index; GLP = glucagon-like peptide; HOMA-IR = homeostatic model assessment for insulin resistance; MRI = magnetic resonance imaging; NAFLD = nonalcoholic fatty liver disease; NAS = NAFLD Activity Score; PDFF = proton density fat fraction; VO2 = oxygen consumption. Continuous variables reported as geometric mean (95%CI) unless indicated. No subjects were taking pioglitazone or obeticholic acid. All p-values were >0.05 for baseline characteristics between groups.